问题 › 该招聘还是外包？ › HealthTech与数字健康
判断标准不是成本。而是该能力是否影响风险收入分成或归因结果，以至于拥有它能改变结果风险上的位置。 数字健康公司更难的地方在于结构：结果风险签署速度快于公司能否承担它的学习速度——12个月测量窗口对11个月销售周期。因此任何可信答案都必须同时把握风险收入分成和参与率，而这正是大多数内部分析停下的原因，因为两者存在于不同系统。
判断标准不是成本。而是该能力是否影响风险收入分成或归因结果，以至于拥有它能改变结果风险上的位置。 数字健康公司更难的地方在于结构：结果风险签署速度快于公司能否承担它的学习速度——12个月测量窗口对11个月销售周期。因此任何可信答案都必须同时把握风险收入分成和参与率，而这正是大多数内部分析停下的原因，因为两者存在于不同系统。
招聘还是外包通常按每小时成本争论，而这是最不关键的输入。外包职能在低利用率时通常更便宜，高利用率时则更贵，所以诚实的比较取决于已注册会员数量和公司必须预测的参与率。
决定性问题是与公司实际出售内容是否接近。触及归因结果或客户参与率体验、或积累结果风险知识的能力，即使溢价也值得拥有。其余都是采购决策。
第三个因素是方差。拥有职能可控制PMPM和客户流失的质量与时效；外包则换取灵活性。哪种更重要，取决于测量窗口是否向付款方揭示方差。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 辩论完全围绕小时费率，而非风险收入分成。
✓ 拟聘岗位的利用率被假设，而非从340,000名已注册会员的当前参与率估算。
✓ 该职能触及归因结果或驱动客户流失的客户体验。
通常会让情况更糟的做法。 外包积累结果风险知识的职能——它每年成本更低，却在销售周期中逐年削弱。
It is for you if you run or finance a digital health company and the debate is being conducted entirely on hourly rates. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Organizational Alignment Model, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
在全负荷内部成本低于同等产出外部费率时的利用率。明确算出这个盈亏平衡点——它通常比人们假设的更低，辩论到此结束。
任何积累的知识构成所售内容的一部分。失去它不是成本线，而是你能收取的价格缓慢下降。
看方差而非平均值。外包工作平均水平往往相当，但分布更宽，这与客户是否注意到同样重要。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית